Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Disaggregation of Revenue [Line Items]
Net sales	$ 3,569.0	$ 3,785.9	$ 6,812.2	$ 7,439.4
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,284.5	2,363.1	4,401.4	4,672.2
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,284.5	1,422.8	2,410.8	2,767.2
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	387.9	348.4	775.9	737.3
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	182.7	161.9	355.0	338.2
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	136.8	115.5	233.5	195.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	128.1	124.3	240.7	238.5
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	100.3	106.1	198.8	206.8
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	91.4	78.2	173.8	153.2
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	70.0	72.2	133.4	144.4
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	63.1	62.7	122.4	122.1
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	61.1	58.9	121.3	116.9
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	40.7	45.6	77.8	88.1
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	66.6	54.5	124.9	109.7
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	48.4	55.0	91.2	103.2
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	33.9	35.4	66.2	69.9
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	41.6	36.9	74.9	69.9
Developed Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,121.4	1,233.8	2,141.2	2,412.6
Developed Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	997.9	1,085.4	1,869.8	2,072.0
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	586.5	535.7	1,139.3	1,077.5
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	2.4	3.3	5.1	5.4
Japan, Australia and New Zealand Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	160.5	198.4	302.3	382.5
Japan, Australia and New Zealand Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	145.2	151.2	279.5	284.9
Emerging Markets Segment | Brands
Disaggregation of Revenue [Line Items]
Net sales	416.1	395.2	818.6	799.6
Emerging Markets Segment | Generics
Disaggregation of Revenue [Line Items]
Net sales	139.0	182.9	256.4	404.9
Operating Segment | Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,119.3	2,319.2	4,011.0	4,484.6
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	588.9	539.0	1,144.4	1,082.9
Operating Segment | Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	305.7	349.6	581.8	667.4
Operating Segment | Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 555.1	$ 578.1	$ 1,075.0	$ 1,204.5